{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:14:07Z","timestamp":1791220447313,"version":"4.1.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,2,1]]},"DOI":"10.1309\/980m-e24r-v19k-595d","type":"journal-article","created":{"date-parts":[[2003,1,8]],"date-time":"2003-01-08T15:52:37Z","timestamp":1042041157000},"page":"251-258","source":"Crossref","is-referenced-by-count":82,"title":["HER-2\/neu Protein Expression in Breast Cancer Evaluated by Immunohistochemistry"],"prefix":"10.1093","volume":"113","author":[{"given":"Timothy W.","family":"Jacobs","sequence":"first","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen M.","family":"Gown","sequence":"additional","affiliation":[{"name":"PhenoPath Laboratories and IRIS, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Yaziji","sequence":"additional","affiliation":[{"name":"PhenoPath Laboratories and IRIS, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Schnitt","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2000,2,1]]},"reference":[{"key":"E00001","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.1989.7.8.1120","volume":"7","author":"Tandon","year":"1989","unstructured":"Tandon AK, Clark GM, Chamness GC, et al. HER-2\/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7:1120-1128.","journal-title":"J Clin Oncol"},{"key":"E00002","first-page":"3296","volume":"51","author":"McCann","year":"1991","unstructured":"McCann AH, Dervan PA, O'Regan M, et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res. 1991;51:3296-3303.","journal-title":"Cancer Res"},{"key":"E00003","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ijc.2910490504","volume":"49","author":"Kallioniemi","year":"1991","unstructured":"Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991;49: 650-655.","journal-title":"Int J Cancer"},{"key":"E00004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ijc.2910490109","volume":"49","author":"Rilke","year":"1991","unstructured":"Rilke F, Colnaghi MI, Cascinelli N, et al. Prognostic significance of HER-2\/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991;49:44-49.","journal-title":"Int J Cancer"},{"key":"E00005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/oxfordjournals.annonc.a057824","volume":"2","author":"Anbazhagan","year":"1991","unstructured":"Anbazhagan R, Gelber RD, Bettelheim R, et al. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol. 1991;2:47-53.","journal-title":"Ann Oncol"},{"key":"E00006","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.1992.10.7.1049","volume":"10","author":"Gusterson","year":"1992","unstructured":"Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992;10:1049-1056.","journal-title":"J Clin Oncol"},{"key":"E00007","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1200\/JCO.1992.10.5.686","volume":"10","author":"Gasparini","year":"1992","unstructured":"Gasparini G, Gullick WJ, Bevilacqua P, et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol. 1992;10:686-695.","journal-title":"J Clin Oncol"},{"key":"E00008","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9","volume":"73","author":"Tetu","year":"1994","unstructured":"Tetu B, Brisson J. Prognostic significance of HER-2\/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer. 1994;73:2359-2365.","journal-title":"Cancer"},{"key":"E00009","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1990.8.1.103","volume":"8","author":"Paik","year":"1990","unstructured":"Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103-112.","journal-title":"J Clin Oncol"},{"key":"E00010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/path.1711630205","volume":"163","author":"Dykins","year":"1991","unstructured":"Dykins R, Corbett IP, Henry JA, et al. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol. 1991;163:105-110.","journal-title":"J Pathol"},{"key":"E00011","first-page":"4960","volume":"53","author":"Press","year":"1993","unstructured":"Press MF, Pike MC, Chazin VR, et al. Her-2\/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53:4960-4970.","journal-title":"Cancer Res"},{"key":"E00012","first-page":"7147","volume":"49","author":"Thor","year":"1989","unstructured":"Thor AD, Schwartz LH, Koerner FC, et al. Analysis of c-erbB-2 expression in breast carcinomas with clinical followup. Cancer Res. 1989;49:7147-7152.","journal-title":"Cancer Res"},{"key":"E00013","first-page":"2087","volume":"49","author":"Wright","year":"1989","unstructured":"Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989;49:2087-2090.","journal-title":"Cancer Res"},{"key":"E00014","first-page":"4332","volume":"50","author":"Borg","year":"1990","unstructured":"Borg A, Tandon AK, Sigurdsson H, et al. HER-2\/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50:4332-4337.","journal-title":"Cancer Res"},{"key":"E00015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/bjc.1991.101","volume":"63","author":"Lovekin","year":"1991","unstructured":"Lovekin C, Ellis IO, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer [published correction appears in Br J Cancer. 1991;64:202]. Br J Cancer. 1991;63:439-443.","journal-title":"Br J Cancer"},{"key":"E00016","first-page":"1441","volume":"14","author":"Giai","year":"1994","unstructured":"Giai M, Roagna R, Ponzone R, et al. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res. 1994;14:1441-1450.","journal-title":"Anticancer Res"},{"key":"E00017","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0046-8177(96)90224-5","volume":"27","author":"O'Malley","year":"1996","unstructured":"O'Malley FP, Saad Z, Kerkvliet N, et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Hum Pathol. 1996;27:955-963.","journal-title":"Hum Pathol"},{"key":"E00018","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.1997.15.8.2894","volume":"15","author":"Press","year":"1997","unstructured":"Press MF, Bernstein L, Thomas PA, et al. HER-2\/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-2904.","journal-title":"J Clin Oncol"},{"key":"E00019","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.1998.16.4.1340","volume":"16","author":"Andrulis","year":"1998","unstructured":"Andrulis IL, Bull SB, Blackstein ME, et al. neu\/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer: Toronto Breast Cancer Study Group. J Clin Oncol. 1998;16:1340-1349.","journal-title":"J Clin Oncol"},{"key":"E00020","first-page":"26A","author":"Ross, JS","year":"1998","unstructured":"Ross JS, Muraca PJ, Jaffe D, et al. Multivariate analysis of prognostic factors in lymph node negative breast cancer [abstract]. Mod Pathol. 1998;11:26A.","journal-title":"Mod Pathol"},{"key":"E00021","first-page":"944","volume":"51","author":"Clark","year":"1991","unstructured":"Clark GM, McGuire WL. Follow-up study of HER-2\/neu amplification in primary breast cancer. Cancer Res. 1991;51:944-948.","journal-title":"Cancer Res"},{"key":"E00022","first-page":"556","volume":"51","author":"Paterson","year":"1991","unstructured":"Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991;51:556-567.","journal-title":"Cancer Res"},{"key":"E00023","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.1992.10.4.599","volume":"10","author":"Allred","year":"1992","unstructured":"Allred DC, Clark GM, Tandon AK, et al. HER-2\/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10:599-605.","journal-title":"J Clin Oncol"},{"key":"E00024","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/bjc.1993.114","volume":"67","author":"Bianchi","year":"1993","unstructured":"Bianchi S, Paglierani M, Zampi G, et al. Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer. 1993;67:625-629.","journal-title":"Br J Cancer"},{"key":"E00025","first-page":"98A","volume":"17","author":"Slamon","year":"1998","unstructured":"Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER+\/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc ASCO. 1998;17:98A.","journal-title":"Proc ASCO"},{"key":"E00026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235:177-182.","journal-title":"Science"},{"key":"E00027","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.","journal-title":"Science"},{"key":"E00028","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/bjc.1991.103","volume":"63","author":"Winstanley","year":"1991","unstructured":"Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer. 1991;63:447-450.","journal-title":"Br J Cancer"},{"key":"E00029","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.1993.11.10.1936","volume":"11","author":"Seshadri","year":"1993","unstructured":"Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2\/neu oncogene amplification in primary breast cancer. J Clin Oncol. 1993;11:1936-1942.","journal-title":"J Clin Oncol"},{"key":"E00030","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V","volume":"74","author":"Hartmann","year":"1994","unstructured":"Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer: results from a randomized adjuvant treatment protocol. Cancer. 1994;74:2956-2963.","journal-title":"Cancer"},{"key":"E00031","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","volume":"16","author":"Pegram","year":"1998","unstructured":"Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659-2671.","journal-title":"J Clin Oncol"},{"key":"E00032","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","volume":"16","author":"Pegram","year":"1998","unstructured":"Stal O, Sullivan S, Wingren S, et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer. 1995;31A:2185-2190.","journal-title":"J Clin Oncol"},{"key":"E00033","first-page":"1509","volume":"2","author":"Bitran","year":"1996","unstructured":"Bitran JD, Samuels B, Trujillo Y, et al. Her2\/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (&gt;10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res. 1996;2:1509-1513.","journal-title":"Clin Cancer Res"},{"key":"E00034","first-page":"823","volume":"11","author":"Tetu","year":"1998","unstructured":"Tetu B, Brisson J, Plante V, et al. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol. 1998;11:823-830.","journal-title":"Mod Pathol"},{"key":"E00035","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199405053301802","volume":"330","author":"Muss","year":"1994","unstructured":"Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.","journal-title":"N Engl J Med"},{"key":"E00036","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/jnci\/90.18.1346","volume":"90","author":"Thor","year":"1998","unstructured":"Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346-1360.","journal-title":"J Natl Cancer Inst"},{"key":"E00037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0304-3835(94)90194-5","volume":"81","author":"Borg","year":"1994","unstructured":"Borg A, Baldetorp B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 1994;81:137-144.","journal-title":"Cancer Lett"},{"key":"E00038","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/0046-8177(92)90032-X","volume":"23","author":"Singleton","year":"1992","unstructured":"Singleton TP, Niehans GA, Gu F, et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol. 1992;23:1141-1150.","journal-title":"Hum Pathol"},{"key":"E00039","first-page":"673","volume":"6","author":"Kerns","year":"1993","unstructured":"Kerns BJ, Jordan PA, Huper G, et al. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Mod Pathol. 1993;6:673-678.","journal-title":"Mod Pathol"},{"key":"E00040","first-page":"128","volume":"4","author":"Bobrow","year":"1996","unstructured":"Bobrow LG, Happerfield LC, Millis RR. Comparison of immunohistological staining with different antibodies to the c-erbB-2 oncoprotein. Appl Immunohistochemistry. 1996;4:128-134.","journal-title":"Appl Immunohistochemistry"},{"key":"E00041","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0344-0338(11)80508-X","volume":"189","author":"Heatley","year":"1993","unstructured":"Heatley M, Maxwell P, Whiteside C, et al. C-erbB-2 oncogene product expression depends on tumour type and is related to oestrogen receptor and lymph node status in human breast carcinoma. Pathol Res Pract. 1993;189:261-266.","journal-title":"Pathol Res Pract"},{"key":"E00042","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/path.1711730111","volume":"173","author":"Penault-Llorca","year":"1994","unstructured":"Penault-Llorca F, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol. 1994;173:65-75.","journal-title":"J Pathol"},{"key":"E00043","first-page":"97A","volume":"17","author":"Cobleigh","year":"1998","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc ASCO. 1998;17:97A.","journal-title":"Proc ASCO"},{"key":"E00044","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.1992.10.7.1044","volume":"10","author":"Toikkanen","year":"1992","unstructured":"Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992;10:1044-1048.","journal-title":"J Clin Oncol"},{"key":"E00045","first-page":"419","volume":"12","author":"Tiwari","year":"1992","unstructured":"Tiwari RK, Borgen PI, Wong GY, et al. HER-2\/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 1992;12:419-425.","journal-title":"Anticancer Res"},{"key":"E00046","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/1097-0142(19920615)69:12<2953::AID-CNCR2820691214>3.0.CO;2-U","volume":"69","author":"Noguchi","year":"1992","unstructured":"Noguchi M, Koyasaki N, Ohta N, et al. C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer. 1992;69:2953-2960.","journal-title":"Cancer"},{"key":"E00047","first-page":"434","year":"1999","unstructured":"Roche PC, Ingle JN. Increased HER2 with U.S. Food and Drug Administration-approved antibody [letter]. J Clin Oncol. 1999;17:434.","journal-title":"J Clin Oncol"},{"key":"E00048","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/jcp.47.9.816","volume":"47","author":"Kay","year":"1994","unstructured":"Kay EW, Walsh CJ, Cassidy M, et al. C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol. 1994;47:816-822.","journal-title":"J Clin Pathol"},{"key":"E00049","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/00313029400169611","volume":"26","author":"Busmanis","year":"1994","unstructured":"Busmanis I, Feleppa F, Jones A, et al. Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. Pathology. 1994;26:261-267.","journal-title":"Pathology"},{"key":"E00050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1634\/theoncologist.3-4-237","volume":"3","author":"Ross","year":"1998","unstructured":"Ross JS, Fletcher JA. The HER-2\/neu oncoprotein in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998;3:237-252.","journal-title":"Oncologist"},{"key":"E00051","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/90.18.1320","volume":"90","author":"Clark","year":"1998","unstructured":"Clark GM. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status [editorial]? J Natl Cancer Inst. 1998;90:1320-1321.","journal-title":"J Natl Cancer Inst"},{"key":"E00052","first-page":"223","volume":"1","author":"Haerslev","year":"1993","unstructured":"Haerslev T, Jacobsen GK. Microwave processing of formalin-fixed and paraffin-embedded sections improves the immunoreactivity of c-erbB-2 oncoprotein in breast carcinoma. Appl Immunohistochem. 1993;1:223-226.","journal-title":"Appl Immunohistochem"},{"key":"E00053","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00665980","volume":"35","author":"Quenel","year":"1995","unstructured":"Quenel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat. 1995;35:283-291.","journal-title":"Breast Cancer Res Treat"},{"key":"E00054","first-page":"6941","volume":"49","author":"Ro","year":"1989","unstructured":"Ro JS, el-Naggar A, Ro JY, et al. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res. 1989;49:6941-6944.","journal-title":"Cancer Res"},{"key":"E00055","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/bjc.1991.102","volume":"63","author":"O'Reilly","year":"1991","unstructured":"O'Reilly SM, Barnes DM, Camplejohn RS, et al. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer. 1991;63:444-446.","journal-title":"Br J Cancer"},{"key":"E00056","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/1097-0142(19950315)75:6<1320::AID-CNCR2820750614>3.0.CO;2-C","volume":"75","author":"Rosen","year":"1995","unstructured":"Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemical detection of HER2\/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features, and prognosis. Cancer. 1995;75:1320-1326.","journal-title":"Cancer"},{"key":"E00057","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1200\/JCO.1999.17.7.1983","volume":"17","author":"Jacobs","year":"1999","unstructured":"Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2\/neu status of breast cancers using the United States Food and Drug Administration- approved scoring system. J Clin Oncol. 1999;17:1983-1987.","journal-title":"J Clin Oncol"},{"key":"E00058","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","author":"Elston, CW","year":"1991","unstructured":"Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.","journal-title":"Histopathology"},{"key":"E00059","first-page":"461","author":"Clark, GM","year":"1996","unstructured":"Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. Philadelphia, PA: Lippincott-Raven; 1996:461-485."},{"key":"E00060","first-page":"461","author":"Clark, GM","year":"1996","unstructured":"Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2\/neu in breast cancer J Clin Oncol. 1999;17:1974-1982."},{"key":"E00061","first-page":"1027","volume":"16","author":"Albanell","year":"1996","unstructured":"Albanell J, Bellmunt J, Molina R, et al. Node-negative breast cancers with p53(-)\/HER2-neu(-) status may identify women with very good prognosis. Anticancer Res. 1996;16:1027-1032.","journal-title":"Anticancer Res"},{"key":"E00062","first-page":"121","volume":"21","author":"Solomides","year":"1999","unstructured":"Solomides CC, Zimmerman R, Bibbo M. Semiquantitative assessment of c-erbB-2 (HER-2) status of cytology specimens and tissue sections from breast carcinoma. Anal Quant Cytol Histol. 1999;21:121-125.","journal-title":"Anal Quant Cytol Histol"},{"key":"E00063","first-page":"13","volume":"12","author":"Graziano, C","year":"1998","unstructured":"Graziano C. HER-2 breast assay, linked to Herceptin, wins FDA's okay. CAP Today. 1998;12:13-16.","journal-title":"CAP Today"},{"key":"E00064","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/90.18.1361","volume":"90","author":"Paik","year":"1998","unstructured":"Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361-1370.","journal-title":"J Natl Cancer Inst"},{"key":"E00065","first-page":"97A","volume":"17","author":"Ravdin","year":"1998","unstructured":"Ravdin PM, Green S, Albain KS, et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with Tamoxifen (T) alone [abstract]. Proc ASCO. 1998;17:97A.","journal-title":"Proc ASCO"},{"key":"E00066","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/bjc.1992.22","volume":"65","author":"Wright","year":"1992","unstructured":"Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992;65:118-121.","journal-title":"Br J Cancer"},{"key":"E00067","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.1996.14.10.2702","volume":"14","author":"Carlomagno","year":"1996","unstructured":"Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14:2702-2708.","journal-title":"J Clin Oncol"},{"key":"E00068","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JCO.1998.16.2.462","volume":"16","author":"Sjogren","year":"1998","unstructured":"Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16:462-469.","journal-title":"J Clin Oncol"},{"key":"E00069","first-page":"1527","author":"Lundy, J","year":"1991","unstructured":"Lundy J, Schuss A, Stanick D, et al. Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer: correlation with clinicopathologic parameters. Am J Pathol. 1991;138:1527-1534.","journal-title":"Am J Pathol"},{"key":"E00070","first-page":"2771","volume":"54","author":"Press","year":"1994","unstructured":"Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2\/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777.","journal-title":"Cancer Res"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/113\/2\/251\/24980494\/ajcpath113-0251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T04:08:42Z","timestamp":1583986122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/113\/2\/251\/1757825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2,1]]},"references-count":70,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2000,2,1]]},"published-print":{"date-parts":[[2000,2,1]]}},"URL":"https:\/\/doi.org\/10.1309\/980m-e24r-v19k-595d","relation":{},"ISSN":["1943-7722","0002-9173"],"issn-type":[{"value":"1943-7722","type":"electronic"},{"value":"0002-9173","type":"print"}],"subject":[],"published-other":{"date-parts":[[2000,2,1]]},"published":{"date-parts":[[2000,2,1]]}}}